Molecular structure and glass vial preparation | |
| Clinical data | |
|---|---|
| Trade names | Solu-Medrol, Solu-Medrone, Urbason, others |
| Other names | Methylprednisolone hemisuccinate; 6α-Methylprednisolone 21-hemisuccinate |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous injection |
| Drug class | Corticosteroid;Glucocorticoid |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.017.416 |
| Chemical and physical data | |
| Formula | C26H34O8 |
| Molar mass | 474.550 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Methylprednisolone succinate, sold under the brand nameSolu-Medrol among others, is asyntheticglucocorticoidcorticosteroid and acorticosteroid ester—specifically the C21succinateester ofmethylprednisolone—which is used byintravenous administration.[3][4] Methylprednisolone succinate is provided as two differentsalts when used as apharmaceutical drug: asodium salt (methylprednisolone sodium succinate; brand name Solu-Medrol, others) and ahydrogen salt (methylprednisolone hemisuccinate ormethylprednisolone hydrogen succinate; brand name Urbason).[3][4]
Methylprednisolone succinate was approved for medical use in the United States in 1959.[2]